L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 1.1 million before July 12, 2017
Zutphen, The Netherlands, 31 May 2017
ESPERITE (ESP) Q1 consolidated revenue higher compared to budget
EBITDA improved compared to budget as a result of cost control
Zutphen, the Netherlands – 31 May 2017
ESPERITE (ESP) has concluded new agreements with its note holders
Zutphen, the Netherlands – 31 May 2017
ESPERITE N.V. convenes Annual General Meeting of Shareholders
Zutphen, The Netherlands – 23 May 2017
ESPERITE N.V. (Euronext: ESP, “Esperite” or “the Group”) has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company’s website www.esperite.com.
Zutphen, the Netherlands – 23 May 2017
Esperite further delays publication of 2016 Annual Report
Zutphen, The Netherlands – 20 May 2017
Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.
Zutphen, The Netherlands, 19 May 2017
Esperite (ESP) – Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)
Zutphen, The Netherlands, 15 May 2017
The Cell Factory expands its patent portfolio on extracellular vesicles biologic drugs in China.
Esperite’s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases in China. This allows The Cell Factory entering into one of the largest markets of advanced therapeutics with its disruptive technology of the extracellular vesicles products replacing allogenic MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from May 31-June 1, 2017.
Zutphen, The Netherlands – 11 May 2017
CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from 18-21 May, 2017.
Zutphen, The Netherlands – 5 May 2017
